Pfizer Inc. (NYSE:PFE) Shares Purchased by Aviso Wealth Management

Aviso Wealth Management increased its position in Pfizer Inc. (NYSE:PFE) by 0.7% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 80,848 shares of the biopharmaceutical company’s stock after purchasing an additional 573 shares during the period. Pfizer accounts for about 1.3% of Aviso Wealth Management’s holdings, making the stock its 13th biggest holding. Aviso Wealth Management’s holdings in Pfizer were worth $2,262,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in PFE. Olistico Wealth LLC bought a new position in shares of Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter worth $29,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC boosted its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. purchased a new position in Pfizer in the second quarter valued at about $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, September 16th. Wells Fargo & Company raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. UBS Group upped their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Up 0.4 %

NYSE:PFE opened at $29.09 on Friday. The company has a market cap of $164.84 billion, a price-to-earnings ratio of -484.75, a P/E/G ratio of 1.27 and a beta of 0.68. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $34.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The stock’s fifty day moving average price is $29.31 and its two-hundred day moving average price is $28.29.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the company earned $0.67 earnings per share. The company’s revenue was up 2.1% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.